1 / 30

Ultrafiltration Device Study: Impact on Heart Failure Patients' Weight Loss and Dyspnea at 48 Hours

Investigate the effectiveness of an ultrafiltration device in heart failure patients regarding weight loss and dyspnea at 48 hours. The study aims to evaluate primary endpoints of weight loss and dyspnea scores, secondary endpoints including net fluid loss and heart failure worsening in 90 days, and safety endpoints such as changes in serum creatinine and adverse events up to 90 days.

jody
Download Presentation

Ultrafiltration Device Study: Impact on Heart Failure Patients' Weight Loss and Dyspnea at 48 Hours

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Investigators & Sites

  2. Background

  3. Study Hypotheses

  4. Primary End Points

  5. Secondary End Points

  6. MethodsInclusion Criteria

  7. MethodsExclusion Criteria

  8. MethodsStudy Procedures

  9. MethodsStudy Procedures

  10. MethodsUltrafiltration Device

  11. Baseline Demographics and Comorbidities

  12. Baseline Heart Failure Characteristics

  13. Baseline Functional Capacity and Vital Signs

  14. Baseline Laboratory Values

  15. Baseline Medications

  16. Primary End PointWeight Loss at 48 Hr Primary End PointWeight Loss at 48 Hr

  17. Primary End PointDyspnea Score at 48 Hr

  18. Secondary End PointNet Fluid Loss at 48 Hr

  19. Worsening Heart Failure in 90 days

  20. Freedom From Re-hospitalization for Heart Failure

  21. Secondary End Points

  22. Safety End Points: Change in Serum Creatinine

  23. Adverse events up to 90 days

  24. Deaths up to 90 days

  25. Safety End Points

  26. Vasoactive Drugs Requirement

  27. Summary

  28. Conclusions

More Related